China: A recent case-control study published in the Journal of Inflammation Research has shed light on a potential ...

Netherlands: A recent study published in the European Journal of Trauma and Emergency Surgery highlights the potential of ...

In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $99.0, a ...

The sCD13 protein has been previously identified by a rheumatology research team at the University of Michigan as a powerful inducer of inflammation in multiple autoimmune disorders, such as ...

Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of ...

How your immune system really ages — research shows aging brings adaptation not decline and reveals ways to maintain immune ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

In April 2025, Areteia Therapeutics announced a study will assess the efficacy and safety of dexpramipexole as an adjunctive ...

Protalix BioTherapeutics, Inc. (AMEX: PLX) Q1 2025 Earnings Call Transcript May 9, 2025 Protalix BioTherapeutics, Inc. misses ...

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment ...

Protalix BioTherapeutics, Inc.’s PLX share price has dipped by 35.47%, which has investors questioning if this is right time to buy.